{"id":696,"date":"2026-05-14T16:20:41","date_gmt":"2026-05-14T15:20:41","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=696"},"modified":"2026-06-27T12:24:17","modified_gmt":"2026-06-27T11:24:17","slug":"car-t-zelltherapie","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/car-t-zelltherapie\/","title":{"rendered":"Application CAR-T Cell Manufacturing"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"696\" class=\"elementor elementor-696\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7e8e300 e-con e-atomic-element e-flexbox-base e-21e9f79 \" data-id=\"7e8e300\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"7e8e300\">\n    \t\t<div class=\"elementor-element elementor-element-b9efb8c elementor-widget elementor-widget-html\" data-id=\"b9efb8c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- YOAST SEO SETTINGS\nSlug:             applications\/car-t-cell-manufacturing\nFocus Keyword:    CAR-T cell manufacturing human serum AB EMA\/410\/01 single-use bags GMP\nSEO Title (EN):   CAR-T Cell Manufacturing \u2014 Human Serum AB, hPL & Single-Use Bags | SeamlessBio\nMeta Desc (EN):   Complete CAR-T manufacturing guide: Human Serum AB OTC Male (EMA\/410\/01), FBS Tet-Free, hPL, rocker bags. Phase-by-phase product map. GMP documentation. SeamlessBio DACH.\n-->\n<section class=\"sb-app\">\n<style>\n.sb-app,.sb-app *,.sb-app *::before,.sb-app *::after{box-sizing:border-box;}\n.sb-app{background:#fff;padding:70px 40px 90px;font-family:Arial,sans-serif;color:#202020;}\n.sb-app .wrap{max-width:1200px;width:100%;margin:0 auto;}\n.sb-app .bc{display:flex;flex-wrap:wrap;gap:8px;margin:0 0 24px;color:#777;font-size:14px;}\n.sb-app .bc a{color:#18b7b2!important;text-decoration:none!important;font-weight:700;}\n.sb-app .bc strong{color:#111;font-weight:800;}\n.sb-app .hero{padding:64px 56px;margin-bottom:48px;border-radius:30px;background:linear-gradient(135deg,#18b7b2 0%,#65d3cf 52%,#e9fbfa 100%);color:#fff;}\n.sb-app .hero .ey{display:inline-block;margin-bottom:14px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:1.8px;}\n.sb-app .hero h1{margin:0 0 18px;color:#fff;font-size:clamp(26px,3.2vw,40px);line-height:1.1;font-weight:900;letter-spacing:-1px;max-width:840px;}\n.sb-app .hero .sub{max-width:720px;margin:0 0 30px;color:#fff;font-size:17px;line-height:1.65;}\n.sb-app .hbtns{display:flex;flex-wrap:wrap;gap:14px;}\n.sb-app .btn1{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:#18b7b2;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-app .btn1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .btn2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:transparent;border:2px solid #fff;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-app .btn2:hover{background:#fff;color:#139b97!important;transform:translateY(-2px);}\n.sb-app .warn{background:rgba(245,166,35,.1);border-left:4px solid #f5a623;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-app .warn strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n.sb-app .note{background:rgba(24,183,178,.08);border-left:4px solid #18b7b2;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-app .note strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n.sb-app .sec{margin-bottom:34px;padding:34px;border-radius:26px;background:#fff;border:1px solid #eee;}\n.sb-app .sec h2{margin:0 0 14px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .sec h3{margin:14px 0 10px;color:#111;font-size:17px;font-weight:900;}\n.sb-app .sec p{margin:0 0 12px;color:#555;font-size:15px;line-height:1.7;}\n.sb-app .sec ul{margin:0 0 14px 0;padding:0;list-style:none;}\n.sb-app .sec li{position:relative;padding:6px 0 6px 20px;color:#555;font-size:14px;line-height:1.6;}\n.sb-app .sec li::before{content:\"\";position:absolute;left:0;top:14px;width:7px;height:7px;border-radius:50%;background:#18b7b2;}\n.sb-app .tw{overflow-x:auto;margin-top:16px;}\n.sb-app table{width:100%;border-collapse:collapse;font-size:14px;min-width:480px;}\n.sb-app thead th{background:#18b7b2;color:#fff;padding:11px 13px;text-align:left;font-weight:700;}\n.sb-app tbody tr:nth-child(even){background:#f5fffe;}\n.sb-app tbody tr:hover{background:#e8f9f8;}\n.sb-app tbody td{padding:10px 13px;vertical-align:top;border-bottom:1px solid #e5e5e5;line-height:1.5;font-size:13px;}\n.sb-app table a{color:#18b7b2;text-decoration:none;font-weight:600;}\n.sb-app .pl{display:inline-block;background:rgba(24,183,178,.12);color:#18b7b2;font-size:11px;font-weight:900;padding:3px 10px;border-radius:99px;margin-bottom:4px;letter-spacing:.3px;}\n.sb-app .faq{margin-bottom:34px;padding:34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .faq h2{margin:0 0 20px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .faq-item{border-bottom:1px solid #e0e0e0;padding:18px 0;}\n.sb-app .faq-item:last-child{border-bottom:none;padding-bottom:0;}\n.sb-app .faq-q{font-size:15px;font-weight:900;color:#111;margin-bottom:8px;}\n.sb-app .faq-a{font-size:14px;color:#555;line-height:1.7;}\n.sb-app .related{margin-bottom:34px;padding:28px 34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .related h3{margin:0 0 16px;color:#111;font-size:18px;font-weight:900;}\n.sb-app .rel-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:12px;}\n.sb-app .rel-grid a{display:flex;align-items:center;min-height:50px;padding:12px 16px;border-radius:12px;background:#fff;border:1px solid #e0e0e0;color:#111!important;text-decoration:none!important;font-size:13px;font-weight:700;transition:all .2s;}\n.sb-app .rel-grid a:hover{border-color:#18b7b2;color:#139b97!important;}\n.sb-app .hub-back{text-align:center;padding:20px 0 0;border-top:1px solid rgba(24,183,178,.15);margin-bottom:16px;}\n.sb-app .hub-back a{color:#18b7b2;font-size:14px;font-weight:700;text-decoration:none;}\n.sb-app .cta{padding:54px 34px;border-radius:30px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);text-align:center;}\n.sb-app .cta h2{margin:0 0 12px;color:#111;font-size:28px;font-weight:900;}\n.sb-app .cta p{max-width:760px;margin:0 auto 26px;color:#555;font-size:15px;line-height:1.65;}\n.sb-app .ctabtns{display:flex;flex-wrap:wrap;gap:14px;justify-content:center;}\n.sb-app .ctab1,.sb-app .ctab2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:.6px;text-decoration:none!important;transition:all .25s;}\n.sb-app .ctab1{background:#18b7b2;color:#fff!important;}\n.sb-app .ctab1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .ctab2{background:transparent;border:2px solid #18b7b2;color:#18b7b2!important;}\n.sb-app .ctab2:hover{background:#18b7b2;color:#fff!important;transform:translateY(-2px);}\n@media(max-width:1100px){.sb-app .hero{padding:48px 36px;}.sb-app .rel-grid{grid-template-columns:1fr;}}\n@media(max-width:700px){.sb-app{padding:50px 16px 70px;}.sb-app .hero{padding:40px 24px;border-radius:24px;}.sb-app .hero h1{font-size:25px;}.sb-app .hbtns,.sb-app .ctabtns{flex-direction:column;}.sb-app .btn1,.sb-app .btn2,.sb-app .ctab1,.sb-app .ctab2{width:100%;}.sb-app .sec,.sb-app .faq{padding:20px;}.sb-app .cta{padding:36px 20px;}}\n<\/style>\n<div class=\"wrap\">\n  <div class=\"bc\">\n    <a href=\"http:\/\/seamlessbio.de\/\">Home<\/a><span>\/<\/span>\n    <a href=\"https:\/\/www.seamlessbio.de\/applications\/\">Applications<\/a><span>\/<\/span>\n    <strong>CAR-T Cell Manufacturing<\/strong>\n  <\/div>\n\n  <div class=\"hero\">\n    <span class=\"ey\">SeamlessBio \u2014 EMA\/410\/01 Compliant \u00b7 GMP Documented<\/span>\n    <h1>CAR-T Cell Manufacturing \u2014 Serum, Media &amp; Single-Use Bag Selection Guide<\/h1>\n    <p class=\"sub\">Five CAR-T therapies have received FDA approval since 2017. Every stage \u2014 T cell isolation, activation, transduction, expansion, formulation \u2014 requires specific biological materials whose grade and regulatory documentation directly determine process success and compliance. This guide covers the complete workflow from R&amp;D to GMP Phase I\/II.<\/p>\n    <div class=\"hbtns\">\n      <a href=\"https:\/\/www.seamlessbio.de\/about-us\/contact-imprint\/\" class=\"btn1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"btn2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"note\">\n    <strong>EMA\/410\/01 \u2014 The Regulatory Baseline for Serum in CAR-T:<\/strong>\n    EMA guideline EMA\/410\/01 explicitly discourages FBS in ATMP manufacturing. <strong>Human Serum AB OTC Male is the preferred ancillary material for ex vivo T cell expansion.<\/strong> Ph. Eur. 5.2.12 documentation required for all human-derived ancillary materials in GMP-phase manufacturing. SeamlessBio provides full documentation packages on request.\n  <\/div>\n\n  <!-- PHASE TABLE -->\n  <div class=\"sec\">\n    <h2>CAR-T Manufacturing \u2014 Phase Overview &amp; Product Requirements<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Phase<\/th><th>Process Step<\/th><th>Recommended Product<\/th><th>Key Specification<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><span class=\"pl\">R&amp;D<\/span> Process Development<\/td>\n            <td>T cell isolation, activation screening, vector optimisation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a><\/td>\n            <td>Low IgG prevents FcR competition in T cell activation assays \u2014 cost-effective for screening<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">R&amp;D \u2192 GMP<\/span> T Cell Activation<\/td>\n            <td>CD3\/CD28 stimulation, IL-2, pre-expansion<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a> or <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a><\/td>\n            <td>OTC: max growth factors from platelet degranulation. HI: when complement must be inactivated during activation<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Ex Vivo T Cell Expansion<\/td>\n            <td>Large-scale CAR-T expansion in static bags or bioreactors<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a> \u2014 5\u201310%<\/td>\n            <td>Gold standard. AB type (no anti-A\/B lysis), male donors (no hormonal variability), off-the-clot (max native growth factors). EMA\/410\/01 preferred.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Bioreactor Expansion<\/td>\n            <td>Rocking bag bioreactor scale-up (0.5\u201350 L)<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">Rocker Bags 0.5\u2013200 L<\/a><\/td>\n            <td>Corning + HyPerforma compatible. ISO 13485. Gamma sterilised \u226525 kGy ISO 11137. Custom port configurations.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Xeno-Free \/ Serum-Free<\/td>\n            <td>Defined serum-free T cell expansion medium supplement<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a><\/td>\n            <td>Xeno-free albumin carrier. Defined, lot-consistent. No donor variability. ISO 13485 documentation.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Media &amp; Buffer Prep<\/td>\n            <td>Media preparation, buffer formulation, storage<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags 150 mL\u201350 L<\/a><\/td>\n            <td>Closed system. Drop-in Sartorius Flexboy. GMP documentation. ISO 13485 Germany.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Harvest &amp; Formulation<\/td>\n            <td>Cell harvest, wash, cryopreservation medium formulation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags<\/a> + <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA<\/a> in formulation buffer<\/td>\n            <td>Closed transfer into gamma-sterilised bags. HSA\/rHSA prevents cell surface adsorption.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">QC<\/span> Release Testing<\/td>\n            <td>Cytotoxicity, ELISpot, ADCC potency assay<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS VLE \u22641 EU\/mL<\/a> + <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a><\/td>\n            <td>VLE for ELISpot background. Human Serum AB HI for PBMC-based release assays.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- WHY HUMAN SERUM AB MALE OTC -->\n  <div class=\"sec\">\n    <h2>Why Human Serum AB Male OTC is the CAR-T Gold Standard<\/h2>\n    <p>Each specification is mechanistically justified \u2014 not arbitrary.<\/p>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Specification<\/th><th>Why It Matters in CAR-T<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>Type AB<\/strong><\/td>\n            <td>No anti-A or anti-B antibodies. In CAR-T expansion where donor T cells from any blood group are expanded, non-AB serum causes anti-A\/B-mediated agglutination and lysis of residual red blood cells \u2014 elevating background cell death and compromising yield.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Male donors only<\/strong><\/td>\n            <td>Female donor serum contains oestrogen and progesterone that vary with the menstrual cycle. These hormones affect T cell activation thresholds and cytokine production \u2014 introducing lot-to-lot yield variability. Male-only pools eliminate this hormonal interference.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Off-the-Clot (OTC)<\/strong><\/td>\n            <td>OTC preserves maximum platelet-derived growth factors released during clot formation: PDGF, TGF-\u03b2, EGF, IGF-1. These directly amplify T cell activation signals and expansion yield. Centrifuged or platelet-poor preparations have significantly lower growth factor content.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Human (not bovine)<\/strong><\/td>\n            <td>EMA\/410\/01 explicitly discourages FBS. FBS introduces bovine xenogenic antigens that sensitise expanded T cells and generate anti-bovine immune responses in patients post-infusion. Human serum eliminates xenogenic antigen exposure and provides a physiologically matched matrix.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- HUMAN SERUM PORTFOLIO -->\n  <div class=\"sec\">\n    <h2>Human Serum Portfolio for CAR-T \u2014 All Grades Explained<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Product<\/th><th>CAR-T Application<\/th><th>Phase<\/th><th>Key Advantage<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a><\/td>\n            <td>Ex vivo T cell expansion \u2014 primary medium supplement<\/td>\n            <td>R&amp;D \u2192 GMP Phase I\/II<\/td>\n            <td>Max growth factors. No anti-A\/B. No hormonal variability. EMA\/410\/01 preferred.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a><\/td>\n            <td>T cell activation (complement-sensitive protocols). ELISpot and PBMC QC release assays.<\/td>\n            <td>R&amp;D, QC<\/td>\n            <td>56\u00b0C\/30 min \u2014 complement destroyed. No complement-mediated T cell lysis during stimulation.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-platelet-lysate-hpl\">Human Platelet Lysate (hPL)<\/a><\/td>\n            <td>Xeno-free MSC expansion. T cell expansion for fully xeno-free GMP protocols.<\/td>\n            <td>GMP xeno-free<\/td>\n            <td>No animal-derived components. Higher MSC proliferation rate. EMA Annex I xeno-free compliant.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a><\/td>\n            <td>Albumin supplement in defined xeno-free T cell medium. Formulation buffer. GMP cryopreservation.<\/td>\n            <td>GMP Phase I\/II, xeno-free<\/td>\n            <td>No donor variability. No blood-borne pathogen risk. ISO 13485 documentation.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FBS IN CAR-T -->\n  <div class=\"sec\">\n    <h2>FBS in CAR-T \u2014 When Still Used and Which Grade<\/h2>\n    <div class=\"warn\">\n      <strong>\u26a0 EMA\/410\/01:<\/strong> FBS is discouraged in clinical CAR-T manufacturing. For Phase I\/II CTA submissions, human serum or defined xeno-free media are the regulatory standard. FBS is still used in early research, process development, and non-clinical studies where EMA ATMP requirements do not apply.\n    <\/div>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>CAR-T Application<\/th><th>FBS Grade<\/th><th>Why This Grade<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td>Early process development \u2014 T cell activation screening<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a><\/td>\n            <td>Bovine IgG occupies Fc\u03b3R on T cells and APCs \u2014 directly interfering with CD3\/CD28 stimulation signals. Ultra Low IgG eliminates this interference.<\/td>\n          <\/tr>\n          <tr>\n            <td>Tet-On\/Tet-Off inducible CAR constructs, lentiviral packaging<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">FBS Tet-Free &lt;10 ng\/mL<\/a><\/td>\n            <td>Standard FBS contains tetracycline residues at 10\u2013100 ng\/mL \u2014 suppresses Tet-responsive promoters even at ng\/mL levels. Most common hidden cause of failed inducible CAR constructs.<\/td>\n          <\/tr>\n          <tr>\n            <td>ADCC potency assay development<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a><\/td>\n            <td>Bovine IgG competes with therapeutic CAR construct for Fc\u03b3R binding \u2014 must be eliminated from ADCC assay medium.<\/td>\n          <\/tr>\n          <tr>\n            <td>ELISpot \/ PBMC-based potency assays<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Very Low Endotoxin \u22641 EU\/mL<\/a><\/td>\n            <td>Endotoxin activates monocytes \u2014 non-specific IFN-\u03b3 background masks CAR-T-specific cytotoxic response in ELISpot.<\/td>\n          <\/tr>\n          <tr>\n            <td>Non-clinical murine CAR-T studies<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a><\/td>\n            <td>Standard grade for syngeneic mouse tumour models where human serum is not required.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- SINGLE-USE BAGS -->\n  <div class=\"sec\">\n    <h2>Single-Use Bags for CAR-T Manufacturing<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Product<\/th><th>Volume Range<\/th><th>CAR-T Application<\/th><th>Key Specification<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">Rocker Bag<\/a><\/td>\n            <td>0.5\u2013200 L<\/td>\n            <td>Ex vivo T cell expansion on rocking wave bioreactor (Corning, HyPerforma compatible)<\/td>\n            <td>EVA\/LDPE or USP Class VI multilayer PE. Gamma sterilised \u226525 kGy. ISO 13485. Custom port configurations.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Bioprocessing Bags<\/a><\/td>\n            <td>150 mL\u201350 L<\/td>\n            <td>Media preparation, buffer storage, cell transfer, cryopreservation medium storage<\/td>\n            <td>USP Class VI. Gamma sterilised. Drop-in Sartorius Flexboy. ISO 13485 Germany.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/3d-bioprocessing-bags\">3D Bioprocessing Bags<\/a><\/td>\n            <td>50\u20131,000 L<\/td>\n            <td>Large-volume media preparation for clinical-scale CAR-T manufacturing facilities<\/td>\n            <td>MPX tubing. Full GMP documentation package. Gamma sterilised. ISO 13485.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- REGULATORY DOCS -->\n  <div class=\"sec\">\n    <h2>Regulatory Documentation \u2014 What You Need for Phase I\/II CAR-T<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Document<\/th><th>SeamlessBio<\/th><th>Regulatory Requirement<\/th><\/tr><\/thead>\n        <tbody>\n          <tr><td>Certificate of Analysis (CoA)<\/td><td>\u2705 Per lot \u2014 all products<\/td><td>Mandatory \u2014 all ancillary materials<\/td><\/tr>\n          <tr><td>Certificate of Origin (CoO)<\/td><td>\u2705 Per lot<\/td><td>Mandatory \u2014 human-derived material traceability<\/td><\/tr>\n          <tr><td>TSE\/BSE Statement<\/td><td>\u2705 Included<\/td><td>EMA Eudralex Vol. 4 Part IV<\/td><\/tr>\n          <tr><td>Ph. Eur. 5.2.12 Declaration<\/td><td>\u2705 On request<\/td><td>Human-derived ancillary materials for ATMP<\/td><\/tr>\n          <tr><td>Viral Testing Panel<\/td><td>\u2705 Per lot \u2014 HIV, HBV, HCV, CMV, EBV, Parvovirus B19<\/td><td>ICH Q5A \u2014 viral safety of human-derived materials<\/td><\/tr>\n          <tr><td>Batch reservation<\/td><td>\u2705 Up to 6 months \u2014 no cost during evaluation phase<\/td><td>Process validation \u2014 same lot throughout Phase I\/II campaign<\/td><\/tr>\n          <tr><td>Irradiation certificate (Bags)<\/td><td>\u2705 Per shipment \u2014 ISO 11137<\/td><td>Single-use bag sterility documentation<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- SERUM TRANSITION TABLE -->\n  <div class=\"sec\">\n    <h2>Serum Transition: FBS \u2192 Human Serum in CAR-T Protocols<\/h2>\n    <p>For laboratories transitioning from FBS-based to human serum-based CAR-T expansion, a validated stepwise approach minimises expansion disruption:<\/p>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Week<\/th><th>Medium Composition<\/th><th>Monitoring Parameters<\/th><\/tr><\/thead>\n        <tbody>\n          <tr><td><strong>Week 1<\/strong><\/td><td>50% FBS Ultra Low IgG + 50% Human Serum AB OTC Male (same total serum %)<\/td><td>Viability, fold expansion, activation markers (CD25, CD69)<\/td><\/tr>\n          <tr><td><strong>Week 2<\/strong><\/td><td>25% FBS Ultra Low IgG + 75% Human Serum AB OTC Male<\/td><td>Growth curve comparison, cytokine profile (IFN-\u03b3, IL-2, TNF-\u03b1)<\/td><\/tr>\n          <tr><td><strong>Week 3+<\/strong><\/td><td>100% Human Serum AB OTC Male at 5\u201310%<\/td><td>Confirm \u226595% viability, stable fold-expansion, phenotype maintenance (CD4\/CD8, memory markers)<\/td><\/tr>\n          <tr><td><strong>Optional<\/strong><\/td><td>5% \u2192 2% \u2192 0% serum with rHSA supplementation \u2192 fully serum-free xeno-free<\/td><td>Full serum-free protocol validation for GMP Phase I\/II submission<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FAQ -->\n  <div class=\"faq\">\n    <h2>Frequently Asked Questions<\/h2>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why is Human Serum AB Male OTC preferred over AB Female or mixed-gender pools?<\/div>\n      <div class=\"faq-a\">Male-only donor serum eliminates hormonal variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production in a cycle-dependent manner. Mixed-gender or female pools introduce hormonal lot-to-lot variability that manifests as inconsistent CAR-T expansion yields between manufacturing runs \u2014 a critical quality issue in GMP production where process consistency is a regulatory requirement.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Can I use FBS for Phase I\/II CAR-T trials?<\/div>\n      <div class=\"faq-a\">EMA\/410\/01 discourages FBS in clinical ATMP manufacturing and requires justification if animal-derived ancillary materials are used. For Phase I\/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional safety testing. SeamlessBio recommends transitioning to Human Serum AB OTC Male for all GMP-phase CAR-T manufacturing.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why does FBS Tet-Free matter specifically for CAR-T development?<\/div>\n      <div class=\"faq-a\">Standard FBS contains tetracycline residues at 10\u2013100 ng\/mL from bovine husbandry. Tet-On and Tet-Off inducible CAR constructs and lentiviral packaging systems are suppressed at concentrations as low as 1\u201310 ng\/mL. Standard FBS can partially or completely suppress transgene induction \u2014 causing researchers to incorrectly conclude the construct is non-functional. FBS Tet-Free &lt;10 ng\/mL is the only correct grade for any Tet-regulated CAR-T application.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">What batch size of Human Serum AB OTC Male for Phase I CAR-T?<\/div>\n      <div class=\"faq-a\">For Phase I autologous CAR-T (typically 3\u201310 patient batches), a lot reservation of 500 mL to 2 L is usually sufficient at 5\u201310% serum in expansion medium. SeamlessBio holds batch reservations up to 6 months at no cost during the validation phase, allowing lot testing before commitment.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Which single-use bag size for CAR-T rocking bioreactor expansion?<\/div>\n      <div class=\"faq-a\">For autologous CAR-T Phase I manufacturing, 0.5\u20135 L rocker bags are typical \u2014 matching cell numbers from a single patient apheresis. For allogeneic or iPSC-derived CAR-T at larger scale, 10\u201350 L bags are standard. SeamlessBio rocker bags are compatible with Corning and Thermo Fisher HyPerforma rocking platforms in all sizes from 0.5 L to 200 L.<\/div>\n    <\/div>\n  <\/div>\n\n  <!-- RELATED -->\n  <div class=\"related\">\n    <h3>Related Applications &amp; Products<\/h3>\n    <div class=\"rel-grid\">\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/cell-therapy-atmps\">\u2192 Cell Therapy &amp; ATMP Manufacturing \u2014 Full Supply Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/cytotoxicity-assays\">\u2192 Cytotoxicity Assays \u2014 ADCC, CDC, ELISpot<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/ipsc-stem-cell-culture\">\u2192 iPSC &amp; Stem Cell Culture Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">\u2192 Human Serum AB OTC Male<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">\u2192 Rocker Bags 0.5\u2013200 L<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">\u2192 FBS Tet-Free &lt;10 ng\/mL<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"hub-back\"><a href=\"https:\/\/www.seamlessbio.de\/applications\/\">\u2190 All Application Guides Overview<\/a><\/div>\n\n  <div class=\"cta\">\n    <h2>Request Free Test Volumes &amp; GMP Documentation<\/h2>\n    <p>Human Serum AB OTC Male lot-specific viral testing and Ph. Eur. 5.2.12 documentation available on request. Free samples for process development. Batch reservation for Phase I\/II CAR-T programmes.<br>Email: info@seamlessbio.de | +49 851 37932226<\/p>\n    <div class=\"ctabtns\">\n      <a href=\"mailto:info@seamlessbio.de\" class=\"ctab1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"ctab2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n<\/div>\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"FAQPage\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/car-t-cell-manufacturing#faqpage\",\n      \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why is Human Serum AB Male OTC preferred over AB Female or mixed-gender pools?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Male-only donor serum eliminates hormonal variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production in a cycle-dependent manner. Mixed-gender or female pools introduce hormonal lot-to-lot variability that manifests as inconsistent CAR-T expansion yields between manufacturing runs \u2014 a critical quality issue in GMP production where process consistency is a regulatory requirement.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can I use FBS for Phase I\/II CAR-T trials?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"EMA\/410\/01 discourages FBS in clinical ATMP manufacturing and requires justification if animal-derived ancillary materials are used. For Phase I\/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional safety testing. SeamlessBio recommends transitioning to Human Serum AB OTC Male for all GMP-phase CAR-T manufacturing.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why does FBS Tet-Free matter specifically for CAR-T development?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Standard FBS contains tetracycline residues at 10\u2013100 ng\/mL from bovine husbandry. Tet-On and Tet-Off inducible CAR constructs and lentiviral packaging systems are suppressed at concentrations as low as 1\u201310 ng\/mL. Standard FBS can partially or completely suppress transgene induction \u2014 causing researchers to incorrectly conclude the construct is non-functional. FBS Tet-Free &lt;10 ng\/mL is the only correct grade for any Tet-regulated CAR-T application.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What batch size of Human Serum AB OTC Male for Phase I CAR-T?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"For Phase I autologous CAR-T (typically 3\u201310 patient batches), a lot reservation of 500 mL to 2 L is usually sufficient at 5\u201310% serum in expansion medium. SeamlessBio holds batch reservations up to 6 months at no cost during the validation phase, allowing lot testing before commitment.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which single-use bag size for CAR-T rocking bioreactor expansion?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"For autologous CAR-T Phase I manufacturing, 0.5\u20135 L rocker bags are typical \u2014 matching cell numbers from a single patient apheresis. For allogeneic or iPSC-derived CAR-T at larger scale, 10\u201350 L bags are standard. SeamlessBio rocker bags are compatible with Corning and Thermo Fisher HyPerforma rocking platforms in all sizes from 0.5 L to 200 L.\"\n      }\n    }\n      ]\n    },\n    {\n      \"@type\": \"BreadcrumbList\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/car-t-cell-manufacturing#breadcrumb\",\n      \"itemListElement\": [\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 1,\n          \"name\": \"Home\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 2,\n          \"name\": \"Applications\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 3,\n          \"name\": \"CAR-T Cell Manufacturing\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/car-t-cell-manufacturing\"\n        }\n      ]\n    }\n  ]\n}\n<\/script>\n<\/section>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home\/ Applications\/ CAR-T Cell Manufacturing SeamlessBio \u2014 EMA\/410\/01 Compliant \u00b7 GMP Documented CAR-T Cell Manufacturing \u2014 Serum, Media &amp; Single-Use Bag Selection Guide Five CAR-T therapies have received FDA approval [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-696","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAR-T Cell Manufacturing \u2014 GMP Documentation<\/title>\n<meta name=\"description\" content=\"Human Serum AB Male OTC for CAR-T expansion (EMA\/410\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/seamlessbio.de\/de\/car-t-zelltherapie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T Cell Manufacturing \u2014 GMP Documentation\" \/>\n<meta property=\"og:description\" content=\"Human Serum AB Male OTC for CAR-T expansion (EMA\/410\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.\" \/>\n<meta property=\"og:url\" content=\"http:\/\/seamlessbio.de\/de\/car-t-zelltherapie\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-27T11:24:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"9\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/seamlessbio.de\\\/car-t-zelltherapie\\\/\",\"url\":\"http:\\\/\\\/seamlessbio.de\\\/car-t-zelltherapie\\\/\",\"name\":\"CAR-T Cell Manufacturing \u2014 GMP Documentation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-05-14T15:20:41+00:00\",\"dateModified\":\"2026-06-27T11:24:17+00:00\",\"description\":\"Human Serum AB Male OTC for CAR-T expansion (EMA\\\/410\\\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/seamlessbio.de\\\/car-t-zelltherapie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/seamlessbio.de\\\/car-t-zelltherapie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/seamlessbio.de\\\/car-t-zelltherapie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application CAR-T Cell Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAR-T Cell Manufacturing \u2014 GMP Documentation","description":"Human Serum AB Male OTC for CAR-T expansion (EMA\/410\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/seamlessbio.de\/de\/car-t-zelltherapie\/","og_locale":"de_DE","og_type":"article","og_title":"CAR-T Cell Manufacturing \u2014 GMP Documentation","og_description":"Human Serum AB Male OTC for CAR-T expansion (EMA\/410\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.","og_url":"http:\/\/seamlessbio.de\/de\/car-t-zelltherapie\/","og_site_name":"SeamlessBio","article_modified_time":"2026-06-27T11:24:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"9\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/seamlessbio.de\/car-t-zelltherapie\/","url":"http:\/\/seamlessbio.de\/car-t-zelltherapie\/","name":"CAR-T Cell Manufacturing \u2014 GMP Documentation","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-05-14T15:20:41+00:00","dateModified":"2026-06-27T11:24:17+00:00","description":"Human Serum AB Male OTC for CAR-T expansion (EMA\/410\/01). Rocker Bags, 2D Bags, rHSA. Ph. Eur. 5.2.12 documentation. Batch reservation.","breadcrumb":{"@id":"http:\/\/seamlessbio.de\/car-t-zelltherapie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["http:\/\/seamlessbio.de\/car-t-zelltherapie\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/seamlessbio.de\/car-t-zelltherapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Application CAR-T Cell Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"},"image":{"@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=696"}],"version-history":[{"count":8,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/696\/revisions"}],"predecessor-version":[{"id":1831,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/696\/revisions\/1831"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}